case_images: PMC10363863_01
case_images: Timeline of patient's diagnoses and secondary malignancy.. Abbreviations: DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 2.
case_images: 10.1177_23247096231188251-fig1.jpg
case_images: PMC10363863_01_10.1177_23247096231188251-fig1.jpg
case_images: fig1-23247096231188251
case_images: To treat her progressive triple-negative disease in parallel and to treat the possibility of concurrent HER2+ metastatic deposits, she was started on sacituzumab with concurrent trastuzumab/pertuzumab (Figure 1).
case_images: (A) H&E image of patient's DCIS with solid and comedo patterns at 4x magnification. (B) H&E image of patient's high nuclear grade DCIS at 40x magnification. (C) H&E image of grade 3 invasive ductal carcinoma of no special type at 4x magnification. (D) H&E image that demonstrates solid nest of neoplastic cells with significant nuclear pleomorphism in patient's ductal carcinoma at 40X magnification.. Abbreviations: H&E, hematoxylin and eosin; DCIS, ductal carcinoma in situ.
case_images: 10.1177_23247096231188251-fig2.jpg
case_images: PMC10363863_01_10.1177_23247096231188251-fig2.jpg
case_images: fig2-23247096231188251
case_images: A biopsy confirmed triple-negative (ER-/PR-/HER2-) invasive ductal carcinoma (IDC) (Figure 2A-2F). This IDC was ER-/PR-/HER2+, phenotypically different from her recently diagnosed right breast cancer (Figure 2E and 2F). It is suspected that this patient's diagnosis of DCIS and IDC were likely RISM, caused by her original HL treatment regimen (Figure 2).